Shenyang Yamanouchi Pharmaceutical, a joint venture company formed bythe Japanese pharmaceutical firm Yamanouchi and the Shenyang No 1 Pharmaceutical Manufacturing Factory, has completed construction of a new factory in the Shenyang economic and technological development zone in China.
The 70,000-square meter site houses a three-storey ferroconcrete building with state-of-the-art facilities capable of producing up to 30 million solid formulation oral tablets per month. The building also includes a logistics center with storage capacity of around 1,200 square meters and an office and welfare facility of some 1,800 square meters.
Construction costs were around 2.2 billion yen ($19 million) and was initiated in March 1995.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze